362 related articles for article (PubMed ID: 31621030)
1. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. Novel
Lucente E; Liu H; Liu Y; Hu X; Lacivita E; Leopoldo M; Cheng Z
Bioconjug Chem; 2018 May; 29(5):1595-1604. PubMed ID: 29587479
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature.
Chen K; Sun X; Niu G; Ma Y; Yap LP; Hui X; Wu K; Fan D; Conti PS; Chen X
Mol Imaging Biol; 2012 Feb; 14(1):96-105. PubMed ID: 21360213
[TBL] [Abstract][Full Text] [Related]
6. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.
Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR
Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879
[TBL] [Abstract][Full Text] [Related]
7. Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide.
Huang CW; Li Z; Cai H; Shahinian T; Conti PS
Bioconjug Chem; 2011 Feb; 22(2):256-63. PubMed ID: 21244039
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
Cai H; Li Z; Huang CW; Shahinian AH; Wang H; Park R; Conti PS
Bioconjug Chem; 2010 Aug; 21(8):1417-24. PubMed ID: 20666401
[TBL] [Abstract][Full Text] [Related]
9. MicroPET imaging of CD13 expression using a (64)Cu-labeled dimeric NGR peptide based on sarcophagine cage.
Li G; Wang X; Zong S; Wang J; Conti PS; Chen K
Mol Pharm; 2014 Nov; 11(11):3938-46. PubMed ID: 25054774
[TBL] [Abstract][Full Text] [Related]
10. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
[TBL] [Abstract][Full Text] [Related]
11. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
Jackson AB; Nanda PK; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Chen X; Smith CJ
Nucl Med Biol; 2012 Apr; 39(3):377-87. PubMed ID: 22226021
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
13. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
14. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).
Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B
Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
[TBL] [Abstract][Full Text] [Related]
16. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.
Shi J; Kim YS; Zhai S; Liu Z; Chen X; Liu S
Bioconjug Chem; 2009 Apr; 20(4):750-9. PubMed ID: 19320477
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
[TBL] [Abstract][Full Text] [Related]
18. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.
Wei L; Ye Y; Wadas TJ; Lewis JS; Welch MJ; Achilefu S; Anderson CJ
Nucl Med Biol; 2009 Apr; 36(3):277-85. PubMed ID: 19324273
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
20. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
